Ablexis Status
The company was acquired by Deerfield Management through an LBO on June 21, 2018 for an undisclosed sum.
Provider of a drug discovery platform designed to broaden enablement of the efficient discovery of the next generation of breakthrough antibody drugs. The company's AlivaMab Mouse platform is an innovative, next-generation transgenic mouse platform, enabling biotechnology and pharmaceutical companies to efficiently discover and develop the next generation of human therapeutic antibodies to treat human diseases.
Year Founded
2009
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Ablexis News and Updates
AlivaMab Discovery Services Appoints Jane Seagal, PhD, as Vice President of Antibody Discovery
Galveston County Daily News | January 11, 2022
Review of EPO Antibody Decisions January 2021 - December 2021
Lexology | December 31, 2021
AlivaMab Discovery Services Expands Discovery Agreement with IGM Biosciences
Business Wire | November 1, 2021
AlivaMab Discovery Services Expands Drug Discovery Platform with the Launch of New Antibody Engineering Department
Business Wire | May 12, 2021
Ablexis Announces Multi-Target License Agreement with Tanabe Research Laboratories U.S.A.
Business Wire | May 4, 2021
Ablexis's Verticals
Ablexis Primary Industry Sector / Group / Code
Ablexis's Trends
Ablexis Metrics
Growth Rate
SimilarWeb Unique Visitors
Headquarters
-
HQ Address Line 1409 Illinois Street
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94158
-
HQ CountryUnited States
Ablexis's Keywords
mood_badFeed is empty.
Add a review